NOVARTIS’ Lucentis
(ranibizumab) has been approved
by the Australian Therapeutic
Goods Administration (TGA) for the
treatment of visual impairment due
to macular oedema secondary to
retinal vein occlusion (RVO, which is
the result of a blockage forming in
a blood vessel in the retina at the
back of the eye).
Lucentis is available in a single-use
vial for intravitreal use only, and is
already available as a therapy for
wet age-related macular degeneration
(wet AMD) and recently TGA
registered for visual impairment
due to diabetic macular oedema.
The drug is the first anti-VEGF
medication approved for the
treatment of RVO in Australia, and
has been shown to significantly
improve vision and vision-related
quality of life in some patients with
branch RVO (BRVO) and central
RVO.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Mar 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Mar 12
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.